Download MendeleyA Therapeutic Non-self-reactive SARS-CoV-2 Antibody Protects from Lung Pathology in a COVID-19 Hamster Model.
Kreye, J., Reincke, S.M., Kornau, H.C., Sanchez-Sendin, E., Corman, V.M., Liu, H., Yuan, M., Wu, N.C., Zhu, X., Lee, C.D., Trimpert, J., Holtje, M., Dietert, K., Stoffler, L., von Wardenburg, N., van Hoof, S., Homeyer, M.A., Hoffmann, J., Abdelgawad, A., Gruber, A.D., Bertzbach, L.D., Vladimirova, D., Li, L.Y., Barthel, P.C., Skriner, K., Hocke, A.C., Hippenstiel, S., Witzenrath, M., Suttorp, N., Kurth, F., Franke, C., Endres, M., Schmitz, D., Jeworowski, L.M., Richter, A., Schmidt, M.L., Schwarz, T., Muller, M.A., Drosten, C., Wendisch, D., Sander, L.E., Osterrieder, N., Wilson, I.A., Pruss, H.(2020) Cell 183: 1058
- PubMed: 33058755
- DOI: https://doi.org/10.1016/j.cell.2020.09.049
- Primary Citation of Related Structures:
6XKP, 6XKQ - PubMed Abstract:
The emergence of SARS-CoV-2 led to pandemic spread of coronavirus disease 2019 (COVID-19), manifesting with respiratory symptoms and multi-organ dysfunction. Detailed characterization of virus-neutralizing antibodies and target epitopes is needed to understand COVID-19 pathophysiology and guide immunization strategies. Among 598 human monoclonal antibodies (mAbs) from 10 COVID-19 patients, we identified 40 strongly neutralizing mAbs. The most potent mAb, CV07-209, neutralized authentic SARS-CoV-2 with an IC 50 value of 3.1 ng/mL. Crystal structures of two mAbs in complex with the SARS-CoV-2 receptor-binding domain at 2.55 and 2.70 Å revealed a direct block of ACE2 attachment. Interestingly, some of the near-germline SARS-CoV-2-neutralizing mAbs reacted with mammalian self-antigens. Prophylactic and therapeutic application of CV07-209 protected hamsters from SARS-CoV-2 infection, weight loss, and lung pathology. Our results show that non-self-reactive virus-neutralizing mAbs elicited during SARS-CoV-2 infection are a promising therapeutic strategy.
Organizational Affiliation:
German Center for Neurodegenerative Diseases (DZNE) Berlin, 10117 Berlin, Germany; Helmholtz Innovation Lab BaoBab (Brain Antibody-omics and B-cell Lab), 10117 Berlin, Germany; Department of Neurology and Experimental Neurology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Berlin, and Berlin Institute of Health, 10117 Berlin, Germany; Department of Pediatric Neurology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Berlin, and Berlin Institute of Health, 10117 Berlin, Germany. Electronic address: jakob.kreye@dzne.de.
